RCM
TCRX icon

RA Capital Management’s TScan Therapeutics TCRX Stock Holding History

RA Capital Management’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,021,764
Closed -$2.86M – 98
2022
Q1 		$2.86M Sell
1,021,764
-233,553
-19% -$1.01M 0.06% 92
2021
Q4 		$5.65M Hold
1,255,317
– – 0.1% 93
2021
Q3 		$10.5M Buy
+1,255,317
New +$11.6M 0.15% 73

Other funds holding TCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

RA Capital Management's TCRX Position: Q2 2022 in Review

RA Capital Management sold out of TScan Therapeutics (TCRX) in Q2 2022, closing a stake of 1,021,764 shares — an estimated $2.86M sold.

RA Capital Management first reported a position in TCRX in Q3 2021 and held it in 3 quarters. The position peaked at $10.5M in Q3 2021. 24 funds tracked by Wall St. Rank hold TCRX as of Q2 2022.

  • RA Capital Management reported no remaining TScan Therapeutics position as of Q2 2022 after selling out during the quarter.
  • RA Capital Management sold 1,021,764 TScan Therapeutics shares in Q2 2022, an estimated $2.86M.
  • RA Capital Management first reported a position in TScan Therapeutics in Q3 2021 and held it in 3 quarters.
  • RA Capital Management's TScan Therapeutics position peaked at $10.5M in Q3 2021.
  • 24 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2022.

Based on RA Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.